GEM-231

Modify Date: 2024-03-06 17:47:39

GEM-231 structure	Common Name	GEM-231
	CAS Number	255810-66-3	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of GEM-231

GEM231 is an 18mer antisense oligonucleotide targeting the mRNA of the PKA-I (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.

Name	GEM-231

Description	GEM231 is an 18mer antisense oligonucleotide targeting the mRNA of the PKA-I (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> PKA Signaling Pathways >> Stem Cell/Wnt >> PKA
References	[1]. Agrawal S, Kandimalla ER, Yu D, et al. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol. 2002;21(1):65-72. [2]. Mani S, Goel S, Nesterova M, et al. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann N Y Acad Sci. 2003;1002:252-262. [3]. Wang H, Hang J, Shi Z, et al. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol. 2002;21(1):73-80.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> PKA

Signaling Pathways >> Stem Cell/Wnt >> PKA

References

[1]. Agrawal S, Kandimalla ER, Yu D, et al. GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol. 2002;21(1):65-72.

[2]. Mani S, Goel S, Nesterova M, et al. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann N Y Acad Sci. 2003;1002:252-262.

[3]. Wang H, Hang J, Shi Z, et al. Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol. 2002;21(1):73-80.

No Any Chemical & Physical Properties

GEM-231

Use of GEM-231

Names

GEM-231 Biological Activity

Chemical & Physical Properties